Evidence map›Paper›PMID 36546422›Full record

Trial reportHaematologica2023

IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma.

Maria Cristina Pirosa, Marianna Sassone, Barbara Kiesewetter, Armando Lopez Guillermo, Liliana Devizzi, Eva Domingo Domènech, Alessandra Tucci, Donato Mannina, Michele Merli, Antonio Salar and 6 more

Open access · goldAbstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 4 countries.

Maria Cristina PirosaOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona. maria.pirosa@eoc.ch.
Marianna SassoneLymphoma Unit,Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan.
Barbara KiesewetterDepartment of Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna.
Armando Lopez GuillermoDepartment of Hematology, Hospital Clínic de Barcelona, Barcelona.
Liliana DevizziDivision of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan.
Eva Domingo DomènechDepartment of Hematology, Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, Barcelona.
Alessandra TucciDivision of Hematology, AO Spedali Civili di Brescia, Brescia.
Donato ManninaHematology Unit, AO Papardo, Messina.
Michele MerliDepartment of Haematology Ospedale di Circolo di Varese, Varese.
Antonio SalarDepartment of Clinical Hematology Hospital del Mar, Barcelona.
Carlo ViscoDepartment of Medicine, Section of Hematology, University of Verona, Verona.
Fabiana EspositoOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona.
Luisella BonominiInstitute of Oncology Research, Bellinzona.
Emanuele ZuccaOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona.
Andrés J M FerreriLymphoma Unit,Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan.
Markus RadererDepartment of Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna.
Ente Ospedaliero Cantonale · CHIstituto di Ricovero e Cura a Carattere Scientifico San RaffaeleMedical University of Vienna · ATAzienda Ospedaliera Ospedali Riuniti Papardo Piemonte · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITFondazione Audiologica Varese · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITHospital Clínic de Barcelona · ESHospital Del Mar · ESInstitut d'Investigació Biomédica de Bellvitge · ESInstitute of Oncology Research · CHUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ClarithromycinLymphoma, B-Cell, Marginal ZoneAntineoplastic Combined Chemotherapy ProtocolsHumansLenalidomideTreatment OutcomeClarithromycinLenalidomide

Identifiers

PMID36546422
PMCPMC10230432
OpenAlexW4312095759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.